BillionToOne, Inc.
- BLLN · Nasdaq
- Services-Medical Laboratories
- Menlo Park, CA
- 713 employees
- CIK 0002070849
Updated from SEC filings through
Top things to know
Executives
-
Oguzhan Atay Chairman and CEO 4, 2026-09-30 -
Ross Taylor Chief Financial Officer 10-K, 2026-03-11 -
David Tsao Chief Technology Officer 4, 2026-09-28 - Shan Riku Sakakibara Chief Product Officer 4, 2026-09-14
- John Lister Chief Administrative Officer 4, 2025-11-12
- Bosch John Roderick ten SVP of Laboratory Operations 4, 2026-09-28
BillionToOne, Inc. is a U.S. public company in services-medical laboratories (SIC 8071), headquartered in Menlo Park, CA. It trades as BLLN on Nasdaq. Revenue was $305M in the fiscal year ending December 31, 2025, +100.0% from the year before. It reported about 713 employees. Oguzhan Atay is Chairman and CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $305M 10-K, 2026-03-11 | $153M 10-K, 2026-03-11 | $71.7M 10-K, 2026-03-11 |
| Operating income | $16.0M 10-K, 2026-03-11 | -$47.1M 10-K, 2026-03-11 | -$69.5M 10-K, 2026-03-11 |
| SG&A | $143M 10-K, 2026-03-11 | $91.5M 10-K, 2026-03-11 | $64.4M 10-K, 2026-03-11 |
| Net income | $7.5M 10-K, 2026-03-11 | -$41.6M 10-K, 2026-03-11 | -$82.7M 10-K, 2026-03-11 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Oguzhan Atay Co-founder & CEO at BillionToOne | Chairman and CEO | 4, 2026-09-30 |
| Ross Taylor Chief Financial Officer | Chief Financial Officer | 10-K, 2026-03-11 |
| David Tsao | Chief Technology Officer | 4, 2026-09-28 |
| Shan Riku Sakakibara | Chief Product Officer | 4, 2026-09-14 |
| John Lister | Chief Administrative Officer | 4, 2025-11-12 |
| Bosch John Roderick ten | SVP of Laboratory Operations | 4, 2026-09-28 |
| Akshay Rai | Director | 10-K, 2026-03-11 |
| Anthony Pagano | Director | 10-K, 2026-03-11 |
| Firat Ileri | Director | 10-K, 2026-03-11 |
| Krishna Swaroop Kolluri | Director | 10-K, 2026-03-11 |
| Thomas Bremner | Director | 10-K, 2026-03-11 |
What BillionToOne, Inc. does
BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule next-generation sequencing (smNGS) platform achieves what was once thought impossible—detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented Quantitative Counting Templates (QCTs), enabling measurements at the physical limit of detection—the single DNA molecule.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Latest proxy statement | Meeting June 10, 2026 (filed April 21, 2026) | DEF 14A, April 21, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Florham Park, New Jersey) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 2, 2026 | Oguzhan Atay Chairman and CEO | Sale | 30,335 | $3.3M | Form 4, November 4, 2026 |
| November 2, 2026 | David Tsao Chief Technology Officer | Sale | 20,000 | $2.2M | Form 4, November 4, 2026 |
| November 2, 2026 | Bosch John Roderick ten SVP of Laboratory Operations | Sale | 2,834 | $321K | Form 4, November 4, 2026 |
| October 28, 2026 | Oguzhan Atay Chairman and CEO | Sale | 11,000 | $1.3M | Form 4, October 30, 2026 |
| October 15, 2026 | Oguzhan Atay Chairman and CEO | Sale | 11,000 | $1.1M | Form 4, October 16, 2026 |
| October 12, 2026 | Oguzhan Atay Chairman and CEO | Sale | 19,334 | $1.8M | Form 4, October 14, 2026 |
| October 5, 2026 | David Tsao Chief Technology Officer | Sale | 20,000 | $2.2M | Form 4, October 7, 2026 |
| October 5, 2026 | Bosch John Roderick ten SVP of Laboratory Operations | Sale | 2,834 | $298K | Form 4, October 7, 2026 |
Recent 8-K events
- 8-K filed 2026-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-29
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-06-16
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-05-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-04
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-01-12
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-12-09
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2025-11-10
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 8.01 Other events
Frequently asked questions about BillionToOne, Inc.
- What does BillionToOne, Inc. do?
- BillionToOne, Inc. is classified by the SEC as Services-Medical Laboratories (SIC 8071). It is based in Menlo Park, CA.
- What is BillionToOne, Inc.'s revenue?
- $305M for the fiscal year ending December 31, 2025, from its 10-K filed March 11, 2026.
- Is BillionToOne, Inc. profitable?
- BillionToOne, Inc. reported net income of $7.5M for the fiscal year ending December 31, 2025.
- How many employees does BillionToOne, Inc. have?
- About 713 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of BillionToOne, Inc.?
- Oguzhan Atay, Chairman and CEO, as named in a 4 filed September 30, 2026.
- Who is the CFO of BillionToOne, Inc.?
- Ross Taylor, Chief Financial Officer, as named in a 10-K filed March 11, 2026.
- Where is BillionToOne, Inc. headquartered?
- Menlo Park, CA.
- What is BillionToOne, Inc.'s stock ticker?
- BLLN on Nasdaq.
- What industry is BillionToOne, Inc. in?
- Services-Medical Laboratories, SIC code 8071.
- What is BillionToOne, Inc.'s website?
- billiontoone.com. Investor relations: https://investors.billiontoone.com/.
- When does BillionToOne, Inc. report earnings next?
- February 2, 2027. Source: estimate_8k_pattern.
- Is BillionToOne, Inc. a public company?
- Yes. BillionToOne, Inc. files with the SEC under CIK 0002070849 and trades as BLLN.
- Who audits BillionToOne, Inc.?
- PricewaterhouseCoopers LLP, Florham Park, New Jersey, as named in its latest annual report (10-K).
- How many business segments does BillionToOne, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 4, 2026.
- When is BillionToOne, Inc.'s annual shareholder meeting?
- June 10, 2026, per its proxy statement (DEF 14A) filed April 21, 2026.
- Have BillionToOne, Inc. insiders traded stock recently?
- Since August 3, 2026, officers and directors reported 23 open-market sales worth about $31.0M and 0 purchases on Forms 4 and 5. The most recent: Oguzhan Atay (Chairman and CEO) sold 30,335 shares on November 2, 2026.